Lyra Therapeutics, Inc.

NASDAQ
LYRA
Stock
Yield per half year: +2 078.95%
Dividend yield: 0%
Sector: Healthcare

4.14 $

+4.05 $ +4 615.26%
0.0849 $
4.14 $

Min/max per year

Share chart Lyra Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.

more details
The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date 2020-05-01
ISIN US55234L1052
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт link
Change price per day: +4 615.26% (0.0878)
Change price per week: +4 304.26% (0.094)
Change price per month: +4 060.8% (0.0995)
Change price per 3 month: +1 917.54% (0.2052)
Change price per half year: +2 078.95% (0.19)
Change price per year: +1 141.38% (0.3335)
Change price per 3 year: -25.14% (5.53)
Change price per 5 year: -77.69% (18.56)
Change price per year to date: +2 302.79% (0.1723)
All parameters

Grade

Underestimation
Title Value Grade
P/S 8.76 1
P/BV 1.16 9
P/E 0 0
Efficiency
Title Value Grade
ROA, % -89.43 0
ROE, % -184.99 0
ROIC, % 0 0
Dividends
Title Value Grade
Dividend yield 0 0
DSI 0 0
Average dividend growth 0 0
Debt
Title Value Grade
Debt/EBITDA -0.5705 10
Debt/Ratio 0.5182 9
Debt/Equity 4.72 1
Growth impulse
Title Value Grade
Yield Revenue, % 27.83 4
Yield Ebitda, % 172.68 10
Yield EPS, % -44.17 0
More

Insider trading

Main owners

Institutions Volume Share, %
Perceptive Advisors LLC 12 757 562 21.35
Nantahala Capital Management, LLC 8 100 436 13.56
Vestal Point Capital, LP 3 000 000 5.02
Point72 Asset Management, L.P. 3 000 000 5.02
Citadel Advisors Llc 2 861 255 4.79
Samsara BioCapital, LLC 2 780 261 4.65
VR Adviser, LLC 2 575 593 4.31
Rosalind Advisors, Inc. 1 888 720 3.16
PURA VIDA INVESTMENTS, LLC 1 413 242 2.37
Ikarian Capital, LLC 1 254 384 2.1

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Dr. Harlan W. Waksal M.D. Executive Chairman 210.06k 1953 (72 years)
Dr. Maria Palasis Ph.D. CEO, President & Director 942.7k 1965 (60 years)
Dr. Carmichael S. Roberts Jr., Ph.D. Co-Founder N/A 1969 (56 years)
Mr. Jason Cavalier CFO, Treasurer & Secretary 464.11k 1973 (52 years)
Mr. Ray Knox Vice President of Operations N/A
Ms. Vineeta Belanger Ph.D. Senior Vice President of Clinical Affairs N/A
Mr. Ronan P. O'Brien J.D. Chief Legal Officer 1973 (52 years)
Dr. Robert Richard Ph.D. Senior Vice President of Technical Operations 1958 (67 years)
Dr. Robert Kern M.D. Chief Clinical Advisor
Ms. Gloria Cosgrove Senior Vice President of Quality

About company

Address: United States, Watertown. MA, 480 Arsenal Way - Open in google maps, Open in yandex maps
Website: https://lyratherapeutics.com